L-743,872

PreclinicalSmall molecule

Merck & Co.

L-743,872 is one of 46 small molecule programs targeting Esophagitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EsophagitisActive, not recruiting

EsophagitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

54 competitors in Esophagitis

#DrugCompanyPhaseTrials

Prevacid

Takeda

Approved

18 2

Dexilant

Takeda

Approved

4 3

Nexium

DDexcel Pharma Technologies Ltd.

Approved

14 4

Flovent

GSK

Approved

1 5

Aciphex

Akero Therapeutics

Approved

2 6

Protonix

WWyeth-Lederle Vaccines

Approved

1 7

Mucosta

Otsuka

Approved

1 8

Pulmicort

SSalix

Approved

1 9

Alka-Seltzer

Esomeprazole Mg

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness1 trial

Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00005920·70 enrolled

Esophagitis1 trial

A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00005921·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for L-743,872. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-743,872 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-743,872. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Merck & Co.

L-743,872

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness1 trial

Esophagitis1 trial

References

Drug Info

Quick Facts

Related News